Finally, we did not focus on differences between drugs, although we acknowledge that they may have different indications, as reflected by slightly different diabetes prevalence, with a minimum of about 30% for aflibercept to 36% for bevacizumab for anti-VEGF drugs, and up to 42.9% for dexamethasone. This evidence concerns the gene VEGFA and diabetes mellitus.